DBV Technologies S.A. is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with North American operations in Warren, New Jersey. The company is pioneering epicutaneous immunotherapy (EPIT) through its proprietary Viaskin patch technology, which delivers allergens directly to the immune system through intact skin to desensitize patients. Its lead product candidate, Viaskin Peanut, is in late-stage clinical development for the treatment of peanut allergies in children and toddlers. The company's pipeline also includes Viaskin Milk for cow's milk protein allergy and eosinophilic esophagitis (EoE), alongside exploratory applications for other immunological disorders and vaccines. DBV Technologies aims to provide a non-invasive, patient-friendly alternative to traditional allergy treatments.
